Listen on the go
    • Faculty & Disclosures
    Prof. Said Beydoun

    Keck School of Medicine of USC, Los Angeles, CA, USA

    Prof. Said R Beydoun is professor and division chief of neuromuscular medicine at the Department of Neurology at Keck Medicine of University of Southern California (USC), Los Angeles, CA, USA. Prof. Beydoun is also programme director of an ACGME-accredited Clinical Neurophysiology Fellowship. read more

    As a principal investigator, Prof. Beydoun has participated in multiple research clinical trials. His clinical and research areas of expertise in the field of neuromuscular medicine include: amyotrophic lateral sclerosis (ALS), myasthenia gravis, peripheral neuropathy, chronic inflammatory demyelinating polyneuropathy , multifocal motor neuropathy and transthyretin amyloid neuropathy.

    Prof. Beydoun has been published in several scientific journals on topics related to neuromuscular diseases. He is co-editor-in-chief of touchREVIEWS in Neurology. He is also an elected fellow of the American Academy of Neurology and a fellow of the American Association of Neuromuscular and Electrodiagnostic Medicine. Prof. Beydoun is a member of the medical/scientific advisory board of the Myasthenia Gravis Foundation of America and medical director of the Certified ALS Treatment Center of Excellence at Keck USC. He holds board certification by the American Board of Psychiatry and Neurology in Neurology, Clinical Neurophysiology, Neuromuscular Medicine and Pain Medicine.

    Prof. Said Beydoun discloses: Advisory board fees Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Amylyx Pharmaceuticals, Argenx, Biogen, Ionis Pharmaceuticals, Mitsubishi Tanabe Pharma, Octapharma, Takeda and UCB; Grants/research support from Abcuro, Amylyx Pharmaceuticals, Genentech, Healey MGH, Regeneron Pharmaceuticals, Sanofi and UCB; Speaker’s bureau fees from Alexion Pharmaceuticals, Alnylam Pharmaceuticals, Amylyx Pharmaceuticals, Argenx Pharmaceuticals, Grifols and Takeda.
    Dr Pushpa Narayanaswami

    Beth Israel Deaconess Medical Center, Boston, MA, USA

    Dr Pushpa Narayanaswami is an associate professor of neurology at Harvard Medical School and vice-chair of clinical operations at the Department of Neurology, Beth Israel Deaconess Medical Center, Boston, MA. read more

    In her clinical practice, Dr Narayanaswami manages neuromuscular conditions, with special emphasis on myasthenia gravis, myopathies and muscular dystrophies. Her advocacy work seeks to incorporate health services research with healthcare policy to improve patient care.

    Dr Pushpa Narayanaswami is a fellow of the American Academy of Neurology. She is an associate editor for Muscle and Nerve, a member of the level of evidence team of Neurology and serves on the editorial board of Clinical Neuromuscular Disease. She is a member of the Board of Directors of the American Association of Neuromuscular and Electrodiagnostic Medicine, where she also chairs the Quality Improvement and Patient Safety Committee. She serves on the medical and scientific advisory board of the Myasthenia Gravis Foundation of America. She was part of the international panel that developed consensus guidelines for the management of myasthenia gravis. 

    Dr Pushpa Narayanaswami discloses: Advisory board fees from Alexion Pharmaceuticals, Argenx, Dianthus Therapeutics, Janssen and UCB; Consultancy fees from GSK; Grants/research fees from Alexion Pharmaceuticals; Financial support from Sanofi (relationship terminated); Stockholder in Momenta Pharmaceuticals, Pfizer and Viatris (relationship terminated).
    Prof. Heinz Wiendl

    Department of Neurology, University Hospital Münster, Münster, Germany

    Prof. Heinz Wiendl is professor of neurology and chair of the Department of Neurology at the University Hospital of Münster in Germany. read more

    Prof. Wiendl’s research focuses on inflammatory neurodegeneration and immune regulation and protection, as well as monitoring multiple sclerosis and its therapy. In 2017, he was appointed honorary professor at Sydney Medical School and in 2020, he received an honorary doctorate from the Medical Faculty of Mashhad, Iran.

    Prof. Wiendl is a member of numerous scientific and academic advisory boards and expert panels, including editorial boards of international scientific journals in the fields of neurology, neurosciences and immunology. 

    Prof. Heinz Wiendl discloses: Advisory board fees from Alexion Pharmaceuticals, Argenx, Bristol Myers Squibb, Janssen, Merck, Novartis and Sandoz; Consultant fees from Actelion, Argenx, BD, Biogen, EMD Serono, Fondazione, Gossamer Bio, Idorsia, Immunic Therapeutics, Immunovant, Lundbeck, Merck, NexGen, Novartis, PSI CRO, Roche, Sanofi and UCB; Grants/research support from Alexion Pharmaceuticals, Amicus Therapeutics, Argenx, Biogen, CSL Behring, F. Hoffmann-La Roche, Genzyme, Merck, Novartis, Roche and UCB.
    Downloads

    View and download resources from this activity to support your learning and share with colleagues

    Download Slides
    CORRECT!
    Next question
    touchNEUROLOGY touchNEUROLOGY
    • FILTER YOUR SEARCH
    Content Type:
    Speciality:
    More Specialities
    Conference:

    • Neuroimmunology

    EUROPEAN PARTNER

    An Introduction to Neuroimmunology

    Neuroimmunology aims to understand the interactions of the immune and nervous systems. Neural targets involved in many aspects of homeostasis are affected by inflammatory cytokines. The most well-known autoimmune neurological disorder is multiple sclerosis, characterised by an inflammatory autoimmune attack on the myelin sheath and neurodegeneration. Neuroinflammation also plays a role in in Alzheimer’s and Parkinson’s diseases, amyotrophic lateral sclerosis, Huntington’s disease, stroke, chronic depression and schizophrenia. Neuroimmunology is also an important consideration in the design of neural implants. Further understanding of the balance between beneficial and pathological effects of the immune system on the neuronal system will facilitate the development of novel therapies.

    Browse our gallery of video highlights and short articles from the conference hub, providing latest expert insights from major conferences and peer-reviewed articles from the journal portfolio.

    Our supporting partners do not constitute an endorsement of the content on this page.

    Neuroimmunology Content

    Neuroimmunology, Neuromuscular Diseases
    Watch Time: 36 mins
    touchPANEL DISCUSSION
    The complement system in NMOSD and MG: A target for therapeutic benefit?
    CE/CME ACCREDITED Prof. Said Beydoun, Dr Pushpa Narayanaswami, Prof. Heinz Wiendl

    Watch specialists in neurological disorders share their insights on the role of complement and complement therapeutics in patients with neuromyelitis optica spectrum disorder (NMOSD) and myasthenia gravis (MG).

    Learning objectives
    Learning Objectives
    • Describe the role of complement in the pathophysiology of NMOSD and MG
    • Evaluate markers of complement activation as diagnostic and prognostic biomarkers in NMOSD and MG
    • Discuss recently approved and experimental inhibitors of the complement system for the treatment of NMOSD and MG
    Neuroimmunology
    Developed by Touch
    Anthony Béhin, EAN 2023: Safety Profile Overview of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases
    Watch Time: 9 mins

    Dr Anthony Béhin (University Hospitals Pitié Salpêtrière, Paris, France) discusses his abstract on the safety profile of anti-FcRn drugs, in particular efgartigimod, and anti-complement drugs in the treatment of IgG-mediated autoimmune diseases. The abstract ‘EPR-128 Safety Profile Overview of Efgartigimod Clinical Trials in Participants With Diverse IgG-Mediated Autoimmune Diseases’ was presented at the annual European Academy […]

    Neuroimmunology
    A Rare Presentation of Steroid-responsive Encephalopathy Associated with Autoimmune Thyroiditis with Neuropsychiatric Symptoms: A Case Report
    Prashant Bhatele, Manoj Khanal

    touchREVIEWS in Neurology. 2023;19(2):Online ahead of journal publication

    Case study Patient information A 42-year-old woman presented in the emergency department with acute onset whole-body myoclonic jerks for 1 day. On enquiry, the patient’s parents advised that she had a history of depression over the past 15 years. Intermittently, family members had also noticed aggressive and abusive behaviour. She had been evaluated and diagnosed […]

    Epilepsy, Headache Disorders, Multiple Sclerosis, Neuroimmunology, Neuromuscular Diseases, Parkinson's Disease
    Developed by Touch
    Highlights from EAN 2023!
    Watch Time: 2 mins

    Neuroimmunology, Rare Diseases
    Watch Time: 49 mins
    touchSATELLITE SYMPOSIUM
    Latest developments in neuromyelitis optica spectrum disorder: Diagnostics, treatments and patient-centred care
    CE/CME ACCREDITED Dr Dalia Rotstein, Dr Eoin Flanagan, Dr Jeffrey Bennett

    Three experts examine evidence-based approaches for early and accurate diagnosis, appropriate treatment selection and patient-centred care to mitigate the clinical burden of neuromyelitis optica spectrum disorder.

    Learning objectives
    Learning Objectives
    • Recall strategies that facilitate an early and accurate diagnosis of NMOSD
    • Describe how evidence from clinical trials investigating current and emerging treatments for NMOSD informs clinical decision making
    • Select individualized management plans for patients with NMOSD to reduce the patient-reported burden of symptoms
    Multiple Sclerosis, Neuroimmunology
    Watch Time: 35 mins
    touchIN CONVERSATION
    Individualizing long-term treatment and care in active MS: How are therapeutic sequencing options evolving to address unmet needs?
    CE/CME ACCREDITED Dr Ruth Dobson, Dr Ide Smets Translations available:

    Two experts in MS explore the practicalities of therapeutic sequencing options in MS

    Learning objectives
    Learning Objectives
    • Evaluate factors guiding the use of high-efficacy DMTs in the management of active MS
    • Summarize current approaches and safety considerations relating to DMT switching and sequencing in MS
    • Appraise the use of DMTs in women of child-bearing age with MS, including considerations for family planning and implications during pregnancy and beyond
    Neuroimmunology
    Developed by Touch
    Michael Levy: Highlights from the 75th AAN Annual Meeting, 2023
    Watch Time: 1 min

    Dr Michael Levy (Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA) provides his highlights from the 75th AAN Annual Meeting, 2023, in particular that this was the first year to have a myelin oligodendrocyte glycoprotein (MOG) antibody disease focus, with posters on two phase 3 trials, which are expected to be presented in 2026. Disclosures: […]

    Neuroimmunology
    Developed by Touch
    Michael Levy, AAN 2023: Phase 3 CHAMPION-NMOSD subgroup analyses in anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder
    Watch Time: 4 mins

    CHAMPION-NMOSD (NCT04201262) is a study of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder. Ravulizumab binds to the same complement component 5 epitope as eculizumab; however, its longer elimination half-life extends the dosing interval (every 8 versus 2 weeks). In this touchNEUROLOGY interview, we caught up with Dr Michael Levy (Massachusetts General Hospital, […]

    Multiple Sclerosis, Neuroimmunology
    Watch Time: 31 mins
    touchTALKS
    Understanding the pathophysiology of multiple sclerosis and the development of new therapies
    CE/CME ACCREDITED Prof. Tobias Derfuss Translations available:

    Prof. Tobias Derfuss reviews the cellular model of disease in multiple sclerosis, and how pathophysiology can offer novel therapeutic targets.

    Learning objectives
    Learning Objectives
    • Explain the cellular model of disease in multiple sclerosis
    • Explain how the pathobiology of multiple sclerosis drives the development of disease-modifying therapies
    • Summarize the mechanism of action of Bruton’s tyrosine kinase inhibitors and how this may translate into clinical benefits for patients with multiple sclerosis
    Copied to clipboard!
    accredited arrow-down-editablearrow-downarrow_leftarrow-right-bluearrow-right-dark-bluearrow-right-greenarrow-right-greyarrow-right-orangearrow-right-whitearrow-right-bluearrow-up-orangeavatarcalendarchevron-down consultant-pathologist-nurseconsultant-pathologistcrosscrossdownloademailexclaimationfeedbackfiltergraph-arrowinterviewslinkmdt_iconmenumore_dots nurse-consultantpadlock patient-advocate-pathologistpatient-consultantpatientperson pharmacist-nurseplay_buttonplay-colour-tmcplay-colourAsset 1podcastprinter scenerysearch share single-doctor social_facebooksocial_googleplussocial_instagramsocial_linkedin_altsocial_linkedin_altsocial_pinterestlogo-twitter-glyph-32social_youtubeshape-star (1)tick-bluetick-orangetick-red tick-whiteticktimetranscriptup-arrowwebinar Sponsored Department Location NEW TMM Corporate Services Icons-07NEW TMM Corporate Services Icons-08NEW TMM Corporate Services Icons-09NEW TMM Corporate Services Icons-10NEW TMM Corporate Services Icons-11NEW TMM Corporate Services Icons-12Salary £ TMM-Corp-Site-Icons-01TMM-Corp-Site-Icons-02TMM-Corp-Site-Icons-03TMM-Corp-Site-Icons-04TMM-Corp-Site-Icons-05TMM-Corp-Site-Icons-06TMM-Corp-Site-Icons-07TMM-Corp-Site-Icons-08TMM-Corp-Site-Icons-09TMM-Corp-Site-Icons-10TMM-Corp-Site-Icons-11TMM-Corp-Site-Icons-12TMM-Corp-Site-Icons-13TMM-Corp-Site-Icons-14TMM-Corp-Site-Icons-15TMM-Corp-Site-Icons-16TMM-Corp-Site-Icons-17TMM-Corp-Site-Icons-18TMM-Corp-Site-Icons-19TMM-Corp-Site-Icons-20TMM-Corp-Site-Icons-21TMM-Corp-Site-Icons-22TMM-Corp-Site-Icons-23TMM-Corp-Site-Icons-24TMM-Corp-Site-Icons-25TMM-Corp-Site-Icons-26TMM-Corp-Site-Icons-27TMM-Corp-Site-Icons-28TMM-Corp-Site-Icons-29TMM-Corp-Site-Icons-30TMM-Corp-Site-Icons-31TMM-Corp-Site-Icons-32TMM-Corp-Site-Icons-33TMM-Corp-Site-Icons-34TMM-Corp-Site-Icons-35TMM-Corp-Site-Icons-36TMM-Corp-Site-Icons-37TMM-Corp-Site-Icons-38TMM-Corp-Site-Icons-39TMM-Corp-Site-Icons-40TMM-Corp-Site-Icons-41TMM-Corp-Site-Icons-42TMM-Corp-Site-Icons-43TMM-Corp-Site-Icons-44TMM-Corp-Site-Icons-45TMM-Corp-Site-Icons-46TMM-Corp-Site-Icons-47TMM-Corp-Site-Icons-48TMM-Corp-Site-Icons-49TMM-Corp-Site-Icons-50TMM-Corp-Site-Icons-51TMM-Corp-Site-Icons-52TMM-Corp-Site-Icons-53TMM-Corp-Site-Icons-54TMM-Corp-Site-Icons-55TMM-Corp-Site-Icons-56TMM-Corp-Site-Icons-57TMM-Corp-Site-Icons-58TMM-Corp-Site-Icons-59TMM-Corp-Site-Icons-60TMM-Corp-Site-Icons-61TMM-Corp-Site-Icons-62TMM-Corp-Site-Icons-63TMM-Corp-Site-Icons-64TMM-Corp-Site-Icons-65TMM-Corp-Site-Icons-66TMM-Corp-Site-Icons-67TMM-Corp-Site-Icons-68TMM-Corp-Site-Icons-69TMM-Corp-Site-Icons-70TMM-Corp-Site-Icons-71TMM-Corp-Site-Icons-72